Top 10 Blue Chip Stocks To Invest In Right Now

Shutterstock

A few weeks ago we discussed how you can make 12% annually, forever, from stocks. Now let’s apply those lessons to 2017, and highlight five that should do even better (17%+ returns) this year (and likely beyond).

Remember, projecting our returns from any given stock is simple. We simply add together the three ways it can pay us:

Its current dividend.

A future dividend hike.

Share repurchases.

It also helps if the stock is inexpensive, as buybacks deliver more bang for management’s buck. So let’s stick with stocks that are dirt-cheap, trading for 10-times free cash flow (FCF) or less for this exercise.

Here’s an example of a stock ready to return 17% or more over the next year. Blue chip refiner Valero (VLO) has a great management team that knows how to make money no matter what happens with energy prices.

Top 10 Blue Chip Stocks To Invest In Right Now: Nuveen Connecticut Premium Income Municipal Fund(NTC)

Advisors’ Opinion:

  • [By Logan Wallace]

    Media stories about Nuveen Connecticut Premium Income Mun Fd (NYSE:NTC) have trended very positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nuveen Connecticut Premium Income Mun Fd earned a news sentiment score of 0.53 on Accern’s scale. Accern also gave news stories about the investment management company an impact score of 47.4041994466706 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Top 10 Blue Chip Stocks To Invest In Right Now: Carpenter Technology Corporation(CRS)

Advisors’ Opinion:

  • [By Ethan Ryder]

    ValuEngine cut shares of Carpenter Technology (NYSE:CRS) from a buy rating to a hold rating in a research note published on Monday morning.

    Other equities research analysts also recently issued reports about the company. Cowen reiterated a buy rating and issued a $66.00 target price on shares of Carpenter Technology in a research report on Friday, June 1st. Zacks Investment Research upgraded Carpenter Technology from a sell rating to a hold rating in a research report on Monday, April 16th. Deutsche Bank boosted their target price on Carpenter Technology from $47.00 to $49.00 and gave the stock a hold rating in a research report on Wednesday, April 11th. Finally, Longbow Research downgraded Carpenter Technology from a buy rating to a neutral rating and set a $50.00 target price on the stock. in a research report on Monday, June 25th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Carpenter Technology presently has an average rating of Hold and a consensus target price of $56.50.

  • [By Ethan Ryder]

    Titan International (NYSE: TWI) and Carpenter Technology (NYSE:CRS) are both industrial products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

  • [By Logan Wallace]

    Carpenter Technology Co. (NYSE:CRS) VP Timothy Lain sold 1,007 shares of the firm’s stock in a transaction that occurred on Friday, May 4th. The stock was sold at an average price of $55.00, for a total transaction of $55,385.00. Following the completion of the transaction, the vice president now directly owns 11,288 shares of the company’s stock, valued at $620,840. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Top 10 Blue Chip Stocks To Invest In Right Now: State Bank Financial Corporation.(STBZ)

Advisors’ Opinion:

  • [By Logan Wallace]

    State Bank Financial (NASDAQ:STBZ) last issued its quarterly earnings results on Thursday, January 25th. The financial services provider reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.03. State Bank Financial had a return on equity of 9.26% and a net margin of 18.77%. The firm had revenue of $68.16 million during the quarter, compared to the consensus estimate of $65.00 million. analysts expect that State Bank Financial will post 2.18 EPS for the current year.

    TRADEMARK VIOLATION WARNING: “Analysts Set State Bank Financial (STBZ) PT at $34.00” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at www.tickerreport.com/banking-finance/3379591/analysts-set-state-bank-financial-stbz-pt-at-34-00.html.

    State Bank Financial Company Profile

Top 10 Blue Chip Stocks To Invest In Right Now: SmartFinancial, Inc.(SMBK)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on SmartFinancial (SMBK)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Blue Chip Stocks To Invest In Right Now: Enersis S A(ENI)

Advisors’ Opinion:

  • [By Ethan Ryder]

    HSBC set a €18.20 ($21.16) price objective on ENI (ETR:ENI) in a research note published on Monday morning. The brokerage currently has a buy rating on the stock.

  • [By Stephan Byrd]

    Deutsche Bank set a €18.50 ($21.51) price target on ENI (ETR:ENI) in a report released on Thursday. The brokerage currently has a buy rating on the stock.

  • [By Joseph Griffin]

    Headlines about Enel Americas (NYSE:ENI) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Enel Americas earned a news sentiment score of 0.04 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.8569330191595 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Top 10 Blue Chip Stocks To Invest In Right Now: AxoGen, Inc.(AXGN)

Advisors’ Opinion:

  • [By Lee Jackson]

    Jefferies started coverage on this top biotech/medtech firm last year with a Buy rating. AxoGen Inc. (NASDAQ: AXGN) offers surgical solutions for peripheral nerve injuries. It provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. Its portfolio of products includes Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector and Avive Soft Tissue Membrane.

  • [By Joseph Griffin]

    These are some of the media stories that may have impacted Accern’s analysis:

    Get AxoGen alerts:

    Analysts Anticipate AxoGen, Inc (AXGN) Will Announce Earnings of -$0.06 Per Share (americanbankingnews.com) The SVP Sales of AxoGen (NASDAQ: AXGN) is Selling Shares (analystratings.com) BRIEF-Axogen Inc Says On May 15, Board Elected CEO Zaderej To Succeed Grooms As Chairman (reuters.com) AxoGen, Inc (AXGN) SVP Shawn F. Mccarrey Sells 10,000 Shares (americanbankingnews.com) Global Nerve Repair Biomateria Market Report 2018-2023 -Axogen, Integra, Synovis, Collagen Matrix, Polyganics … (talkdailynews.com)

    AxoGen opened at $43.95 on Monday, Marketbeat reports. AxoGen has a fifty-two week low of $13.95 and a fifty-two week high of $46.00. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.81 and a current ratio of 3.32. The company has a market cap of $1.52 billion, a P/E ratio of -141.77 and a beta of -0.04.

  • [By Shane Hupp]

    AxoGen, Inc (NASDAQ:AXGN) – Analysts at William Blair raised their Q2 2018 earnings estimates for AxoGen in a research report issued on Monday, May 14th. William Blair analyst K. Krum now expects that the medical equipment provider will post earnings per share of ($0.04) for the quarter, up from their prior forecast of ($0.05). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for AxoGen’s Q4 2018 earnings at ($0.03) EPS and FY2018 earnings at ($0.25) EPS.

  • [By Lee Jackson]

    This is another biotech/medical technology that Jefferies started coverage on with a Buy rating late last year. AxoGen Inc. (NASDAQ: AXGN) offers surgical solutions for peripheral nerve injuries. The Company provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. Its portfolio of products includes Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector and Avive Soft Tissue Membrane.

Top 10 Blue Chip Stocks To Invest In Right Now: Knowles Corporation(KN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    These are some of the news articles that may have impacted Accern Sentiment’s scoring:

    Get Knowles alerts:

    Head to Head Contrast: Knowles (KN) vs. Sony (SNE) (americanbankingnews.com) Knowles (KN) Given Consensus Rating of “Hold” by Analysts (americanbankingnews.com) Four seniors nab scholarships from Siouxland Officials Association (siouxcityjournal.com) When is Who Dares Wins on BBC One tonight, how old is host Nick Knowles and how does the game show work? (thesun.co.uk) Local students learn the art of architecture (dailytidings.com)

    KN has been the subject of several research analyst reports. Craig Hallum restated a “buy” rating and set a $17.00 price target (down from $20.00) on shares of Knowles in a research report on Thursday, February 8th. Zacks Investment Research lowered Knowles from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. ValuEngine lowered Knowles from a “hold” rating to a “sell” rating in a research report on Monday, April 2nd. JPMorgan Chase lowered their price target on Knowles from $16.00 to $13.50 and set a “neutral” rating for the company in a research report on Tuesday, April 24th. Finally, Lake Street Capital lowered their price target on Knowles from $19.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, February 8th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $17.29.

  • [By Stephan Byrd]

    Sony (NYSE: SNE) and Knowles (NYSE:KN) are both consumer discretionary companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

  • [By Joseph Griffin]

    Liberty Mutual Group Asset Management Inc. lowered its stake in shares of Knowles (NYSE:KN) by 22.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,610 shares of the communications equipment provider’s stock after selling 5,088 shares during the period. Liberty Mutual Group Asset Management Inc.’s holdings in Knowles were worth $222,000 as of its most recent SEC filing.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Knowles (KN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin]

    Shares of Knowles Corporation (NYSE: KN) got a boost, shooting up 15 percent to $12.83 as the company reported Q1 results.

    SVB Financial Group (NASDAQ: SIVB) shares were also up, gaining 19 percent to $305.90 following strong quarterly results.

  • [By Lisa Levin] Gainers
    Genprex, Inc. (NASDAQ: GNPX) jumped 46.7 percent to $16.1331. The low-float small-cap clinical stage gene therapy company saw its stock rally nearly 150 percent from Monday through Thursday. Formal news hasn't been announced this week that would support a triple-digit percentage rally (including more than 200 percent at one point on Thursday) but the quiet period following its initial public offering will expire on May 8.
    Celyad SA (NASDAQ: CYAD) shares gained 24.7 percent to $36.17. Celyad reported the publication of THINK study case report of CYAD-01 Induced Complete Remission in relapsed/refractory AML patient in haematologica.
    DMC Global Inc. (NASDAQ: BOOM) shares jumped 23.2 percent to $39.00 after the company reported upbeat Q1 results and issued upbeat Q2 guidance.
    eHealth, Inc. (NASDAQ: EHTH) gained 21.8 percent to $19.58 as the company posted upbeat Q1 results.
    Enova International, Inc. (NYSE: ENVA) climbed 20.4 percent to $27.20 following Q1 results.
    SVB Financial Group (NASDAQ: SIVB) shares jumped 18.2 percent to $304.135 following strong quarterly results.
    Knowles Corporation (NYSE: KN) gained 13.9 percent to $12.70 as the company reported Q1 results.
    Zymeworks Inc. (NYSE: ZYME) gained 13.8 percent to $17.36.
    Cocrystal Pharma, Inc. (NASDAQ: COCP) rose 11.8 percent to $2.336 after declining 25.09 percent on Thursday.
    ImmunoGen, Inc. (NASDAQ: IMGN) shares surged 11.7 percent to $11.75 after the company announced 'successful completion of interim analysis' for FORWARD I Phase 3 mirvetuximab soravtansine trial.
    Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) gained 9.5 percent to $12.70.
    Expedia Group, Inc. (NASDAQ: EXPE) shares rose 8.5 percent to $115.3801 after the company reported stronger-than-expected earnings for its first quarter on Thursday.
    Sprint Corporation (NYSE: S) shares rose 8.3 percent to $6.50. The stock moved higher after a Reuters report suggested ongoing merger talks with T-M

Top 10 Blue Chip Stocks To Invest In Right Now: Midatech Pharma PLC(MTP)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    But before we show you our pick, here are the top 10 penny stocks to watch this week…

    Penny Stocks Current Share Price (as of Jan. 5) Jan. 2-5 Gain (as of Jan. 5)
    My Size Inc. (Nasdaq: MYSZ) $1.66 152.28%
    Cytori Therapeutics Inc. (Nasdaq: CYTX) $0.47 89.52%
    DelMar Pharmaceuticals Inc. (Nasdaq: DMPI) $1.675 58.02%
    CAS Medical Systems Inc. (Nasdaq: CASM) $1.09 55.71%
    China HGS Real Estate Inc. (Nasdaq: HGSH) $1.83 47.58%
    Aethlon Medical Inc. (Nasdaq: AEMD) $1.56 43.12%
    Midatech Pharma Plc. (Nasdaq: MTP) $1.23 43.01%
    Comstock Holding Cos. Inc. (Nasdaq: CHCI) $1.87 36.5%
    Cenveo Inc. (Nasdaq: CVO) $1.20 31.82%
    EV Energy Partners LP (Nasdaq: EVEP) $0.6844 31.62%

    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it’s completely free…

  • [By Logan Wallace]

    News articles about Midatech Pharma (NASDAQ:MTP) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Midatech Pharma earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.6134155747452 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

  • [By Shane Hupp]

    Media stories about Midatech Pharma (NASDAQ:MTP) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Midatech Pharma earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.0428548550507 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Top 10 Blue Chip Stocks To Invest In Right Now: S&W Seed Company(SANW)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on S&w Seed (SANW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Alico (NASDAQ: ALCO) and S&W Seed (NASDAQ:SANW) are both small-cap consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

  • [By Ethan Ryder]

    S&w Seed (NASDAQ:SANW) – Equities researchers at B. Riley decreased their Q3 2019 earnings per share (EPS) estimates for S&w Seed in a research note issued to investors on Thursday, May 10th. B. Riley analyst S. Sherbetchyan now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their previous forecast of $0.01. B. Riley has a “Buy” rating and a $5.50 price objective on the stock.

  • [By Logan Wallace]

    Alico (NASDAQ: ALCO) and S&W Seed (NASDAQ:SANW) are both small-cap consumer staples companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Top 10 Blue Chip Stocks To Invest In Right Now: Flanigan’s Enterprises Inc.(BDL)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Blink Charging Co. (NASDAQ: BLNK) shares jumped 26.5 percent to $6.9042. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares climbed 17.4 percent to $3.11. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share.
    Flanigan's Enterprises, Inc. (NYSE: BDL) shares jumped 17 percent to $27.97 following Q2 results. Flanigan's Enterprises posted Q2 earnings of $0.75 per share on sales of $29.456 million.
    Borqs Technologies, Inc. (NASDAQ: BRQS) rose 15.8 percent to $8.05 after reporting Q1 results.
    Abaxis, Inc. (NASDAQ: ABAX) jumped 15.3 percent to $82.75. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
    21Vianet Group, Inc. (NASDAQ: VNET) gained 15.1 percent to $6.33.
    Gemphire Therapeutics Inc. (NASDAQ: GEMP) rose 13.8 percent to $6.27.
    Enphase Energy, Inc. (NASDAQ: ENPH) gained 12.8 percent to $5.98. H.C. Wainwright initiated coverage on Enphase Energy with a Buy rating.
    PetIQ Inc (NASDAQ: PETQ) shares surged 12.1 percent to $21.68 after reporting a first-quarter sales beat.
    NF Energy Saving Corporation (NASDAQ: NFEC) climbed 11.6 percent to $2.399.
    Allied Healthcare Products, Inc. (NASDAQ: AHPI) surged 11.4 percent to $3.0643.
    Boot Barn Holdings, Inc. (NYSE: BOOT) gained 11.1 percent to $24.40 after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    Ascena Retail Group, Inc. (NASDAQ: ASNA) rose 10.9 percent to $3.16.
    Sea Limited (NYSE: SE) gained 10.1 percent to $11.71 after reporting Q1 results.
    GEE Group, Inc. (NYSE: JOB) climbed 7.9 percent to $2.61 following Q2 results.
    The ONE Group Hospitality, Inc. (NASDAQ: STKS) gained 7.6 percent to $2.41 after reporting Q1 results.
    Biolinerx Ltd/S ADR (NASDAQ: BLRX) rose 7.3 percent to $0.8798 after the company was granted a patent approval. The clinical-st

Leave a Reply

Your email address will not be published. Required fields are marked *